Allurion Q2 revenue plunges to $3.4M; restructure, potential restatement of non-cash items

ALLURION TECHNOLOGIES, INC.

2025-Q2 EPS reported -$1.79 revenue$8,959,000

Q2 2025 revenue $3.4M, down 71% YoY from $11.8M; gross margin 74% vs 76%.
Operating loss improved to $7.0M from $9.3M YoY; cash $12.7M as of June 30.
Restructuring charges ~$1.5M in Q3 2025; FY2025 guidance being re-evaluated.
Potential restatement of non-cash OCI/other income related to RIFA and convertible notes; no impact on revenue, gross margin, opex, or cash.
New strategy: focus on low-dose GLP-1 combo therapy, muscle mass maintenance; FDA PMA accepted for Allurion Balloon; term sheet signed for drug-eluting balloon.

item 2.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.